Saturday, June 11th, 2016 adds “Global Chronic Lymphocytic Leukemia market 2016-2020” new report to its research database. The report spread across 78 pages with table and figures in it.


The research analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020. Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
- Acute myeloid (or myelogenous) leukemia (AML)
- Chronic myeloid (or myelogenous) leukemia (CML)
- Acute lymphocytic (or lymphoblastic) leukemia (ALL)


Get Report Details at .


The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the generalization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography: 
- Americas

The report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.      


Request a sample copy at .


Key vendors 
- F. Hoffman-La Roche
- AbbVie 
- Teva Pharmaceuticals
- Gilead Sciences
- Novartis
- Johnson & Johnson

Other prominent vendors 
- Altor BioScience
- Amgen
- Arno Therapeutics
- AstraZeneca 
- Bellicum Pharmaceuticals
- Biogen 
- BioLineRx 
- Boston Biomedical
- Celgene
- Emergent BioSolutions 
- Genzyme 
- iDD biotech 
- Immunomedics 
- Infinity Pharmaceuticals
- Innate Pharma 
- Karyopharm Therapeutics
- Ligand Pharmaceuticals 
- MedImmune
- Merck Sharp & Dohme
- Molecular Templates Inc. 
- MorphoSys 
- Ono Pharmaceutical
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals 
- Sunesis Pharmaceuticals
- TG Therapeutics 
- TheraMAB 
- XEME Biopharma 
- Xencor 
- ZIOPHARM Oncology

Market driver 
- Special regulatory designations
- For a full, detailed list, view our report 

Market challenge 
- High cost of therapy
- For a full, detailed list, view our report 

Market trend 
- Rise in development of combination therapies
- For a full, detailed list, view our report   


Inquire more about this report at .


Connect with us @ [email protected] with subject line and your contact details to purchase this report or get your questions answered. OR Call Us @ +1 866-764-2150

Contact Profile

Market Study Report

Market Study Report offers research reports on global or regional markets, competitive information, emerging markets and trends then Market Study Report is the platform that can help you in achieving any of these objectives. Our 24/7 customer support helps clients find the best solution and find best prices for research reports. We help clients with customization of any report at low costs.

Nash Hall
P: 1-866-764-2150


Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Market, Chronic Lymphocytic Leukemia Industry, Chronic Lymphocytic Leukemia Market Trends, Chronic Lymphocytic Leukemia Market Share, Chronic Lymphocytic Leukemia Market Size, Chronic Lymphocytic




More Formats

View QR Code